Markus Aebi
Corporate Officer/Principal bij Institute of Microbiology
Actieve functies van Markus Aebi
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Institute of Microbiology | Corporate Officer/Principal | 22-09-2011 | - |
Loopbaan van Markus Aebi
Eerdere bekende functies van Markus Aebi
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Swiss National Science Foundation | Corporate Officer/Principal | 01-01-1994 | 01-01-1994 |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Hoofd Techniek/Wetenschap/O&O | 01-05-2010 | - |
| Oprichter | 01-05-2010 | - |
Opleiding van Markus Aebi
| University of Zurich | Doctorate Degree |
| California Institute of Technology | Undergraduate Degree |
Statistieken
Internationaal
| Zwitserland | 4 |
| Bulgarije | 2 |
| Verenigde Staten | 2 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
| Swiss National Science Foundation |
- Beurs
- Insiders
- Markus Aebi
- Ervaring
